Saxenda one-month results: what the evidence says about early GLP-1 weight loss

What did @vero_avud actually say?

After one month on Saxenda (liraglutide), this creator reported losing about three kilograms (roughly 6.6 lbs) without changing their diet. They said nausea resolved after two and a half weeks, described significant pain after overeating, and attributed that pain to Saxenda slowing gastric emptying. They framed the slow start as a positive, giving the body time to adjust.

To be clear about the scope here: this is a personal experience video, not a medical claim video. The creator isn't telling you to take Saxenda or prescribing anything. They're documenting what happened to them. That matters when fact-checking, because the standard isn't "did they cite a study" but "is what they described consistent with how this drug actually works?"

Short answer: mostly yes, with one framing issue worth flagging.

Does the science back this up?

The weight loss figure and the nausea timeline are both plausible based on clinical trial data. Three kilograms in a month without dietary changes is within the expected range for early liraglutide treatment, especially at the dose-escalation phase. The gastric emptying explanation is real, though slightly oversimplified.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that patients on liraglutide 3.0 mg lost an average of 8.4 kg over 56 weeks compared to 2.8 kg on placebo. Month-one losses vary widely by individual, but 3 kg is reasonable. Nausea is the most commonly reported adverse event with liraglutide, affecting roughly 40 percent of users in early trials, and it typically diminishes as the body adjusts, which is consistent with the creator's two-and-a-half-week timeline. The mechanism behind the overeating pain is also real: liraglutide delays gastric emptying via GLP-1 receptor activation, meaning food stays in the stomach longer, and pushing past satiety signals can cause genuine discomfort (van Can et al., 2014, International Journal of Obesity).

What did they get wrong (or right)?

The creator got more right than wrong here. The nausea timeline, the satiety mechanism, and the weight loss figure are all consistent with clinical evidence. Give credit where it's due.

The one framing issue: they said Saxenda "keeps your food in your body for longer" as the explanation for the overeating pain. That's partially correct. Delayed gastric emptying is a real liraglutide effect, but the more significant driver of satiety and discomfort is central appetite suppression via GLP-1 receptors in the hypothalamus, combined with slowed gut motility. The stomach isn't just a holding tank that fills up, the brain is also receiving different signals about fullness. This distinction matters because it affects how people think about the drug's risks: it's not just about eating volume, it's about the entire gut-brain signaling axis being altered.

Also worth noting: "I haven't changed anything in my diet" is presented as a positive, and while it's honest, it's not ideal medical practice. GLP-1 medications are typically most effective when paired with dietary changes (Wadden et al., 2013, Obesity). Not wrong, just incomplete as standalone advice to viewers who might take it as a green light to eat freely on Saxenda.

What should you actually know?

If you're watching this video and considering Saxenda, here are the things this creator didn't cover but you probably should understand before starting.

• Saxenda requires a prescription and is indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It's not a casual supplement.
• The drug is dose-escalated over several weeks specifically to reduce nausea, starting at 0.6 mg daily and increasing to 3.0 mg. What dose the creator is on isn't mentioned, which affects how to interpret their results.
• Three kilograms in month one is encouraging, but long-term data shows that many patients regain weight after stopping liraglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism). This is a long-term treatment decision, not a short-term fix.
• The overeating pain the creator described is a real signal worth taking seriously. Pushing past fullness on GLP-1 medications has been associated with increased risk of gastroparesis in susceptible individuals, though this is more commonly flagged with higher-potency GLP-1 agents.
• Saxenda and compounded liraglutide are not the same product. If you're being offered compounded liraglutide at a lower price, that is a different product with different regulatory oversight.

The bottom line

This is one of the more grounded GLP-1 personal experience videos on TikTok. The creator isn't making wild claims, isn't selling anything, and is being reasonably honest about their experience. The science largely supports what they described. The gaps are about mechanism nuance and the missing context around diet, not misinformation. For 117,000 viewers who are curious about what month one actually feels like, this is a relatively responsible share.